Delivery Order SPE2DR25D1004-SPE2DR26FSUC4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,850.92 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on August 27, 2025, with an ultimate completion date of August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a direct procurement of pharmaceutical supplies to support military and federal healthcare operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $6,737.86 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of 36,000 units of Creon DR 100 strength capsules, with an ultimate completion date of October 28, 2025. This firm fixed price delivery order, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement under the company's existing federal supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This firm fixed-price delivery order, valued at $11,775.31, represents a competitively awarded contract with an ultimate completion date of August 29, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied to...
- The Defense Logistics Agency awarded a delivery order valued at $4,132.60 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on September 29, 2025, with a completion date of September 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, valued at $6,347.59, with an ultimate completion date of August 26, 2025. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine procurement of pharmaceutical products supporting federal medical supply chain...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of 36,000 units of Creon DR 100s capsules. This competitively awarded, firm fixed-price delivery order has a ceiling value of $17,155.37 and is scheduled for completion by August 5, 2025. The contract does not include a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a $8,144.34 firm fixed price delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, with an ultimate completion date of September 4, 2025. This non-set-aside contract was awarded competitively and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical support vehicle that runs through December 2026. The product will...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, valued at $8,833.75, with an ultimate completion date of September 26, 2025. This competitively awarded, firm fixed-price delivery order reflects no set-aside designation and is being performed from the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's substantial role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Creon DR 36,000 unit capsules in quantities of 100 units. This non-set-aside, firm fixed-price delivery order has a ceiling value of $6,733.40 and is scheduled for ultimate completion by August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D1004Indefinite Delivery Contract
- SPE2DR25D1004-SPE2DR26FSUC4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $9,788.44. This is a firm fixed price delivery order with an ultimate completion date of October 30, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The award was made without a set-aside designation, indicating that AmerisourceBergen competed for this order on an open basis. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen leverages this comprehensive IDC to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. The company's federal contract portfolio demonstrates consistent capability in delivering both generic and brand-name medications across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 10/29/25 |